Compare LOCO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | LCTX |
|---|---|---|
| Founded | 1980 | 1990 |
| Country | United States | United States |
| Employees | N/A | 77 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.6M | 366.2M |
| IPO Year | 2014 | N/A |
| Metric | LOCO | LCTX |
|---|---|---|
| Price | $10.56 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $14.50 | $4.67 |
| AVG Volume (30 Days) | 189.3K | ★ 958.5K |
| Earning Date | 03-05-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $480,815,000.00 | $10,816,000.00 |
| Revenue This Year | $5.44 | $6.32 |
| Revenue Next Year | $1.64 | $124.49 |
| P/E Ratio | $12.08 | ★ N/A |
| Revenue Growth | 2.09 | ★ 24.05 |
| 52 Week Low | $8.29 | $0.37 |
| 52 Week High | $12.65 | $2.09 |
| Indicator | LOCO | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 46.09 |
| Support Level | $10.56 | $1.58 |
| Resistance Level | $11.24 | $1.71 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 1.38 | 21.57 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.